NASDAQ:LYEL

Lyell Immunopharma Stock Predictions

Healthcare > Biotechnology

Buy LYEL

*Your capital is at risk

$13.00

+0.370 (+2.93%)

At Close: Jun 24, 2026

Currently predicting for Thu, 25 Jun 2026

LYEL Live board

Community Bull/Bear

Target Next close

Join the LYEL prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

LYEL Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For LYEL

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

LYEL Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT LYELL IMMUNOPHARMA, INC.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
IDYA $28.98	20.46%	Jun 12
DHI $146.71	6.39%	Jun 10
EAT $140.46	16.94%	Jun 05
E ETD $20.67	4.79%	Jun 05
TPR $140.47	7.16%	Jun 04

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by